Incidence and Risk Factors for Metabolic Syndrome in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients-a Tertiary Care Center Experience  by Batra, Surabhi et al.
Biol Blood Marrow Transplant 21 (2015) S171eS184LATE EFFECTS/QUALITY OF LIFE/PSYCHOSOCIAL ISSUESFigure 2.213
Bone Mineral Density (BMD) Improves in Survivors in
Their Second Decade Post-Allogeneic Stem Cell
Transplantation and Is Inﬂuenced By Body Mass Index
(BMI) and Age
Prathima Anandi 1, Natasha A. Jain 1, Colin Wu 2, Xin Tian 2,
Priyanka A. Pophali 1, Eleftheria Koklanaris 1, Neil Dunavin 1,
Sawa Ito 1, Robert Q. Le 1, Bipin N. Savani 3, A. John Barrett 1,
Minoo Battiwalla 1. 1 Hematology Branch, National Heart, Lung,
and Blood Institute, NIH, Bethesda, MD; 2Ofﬁce of Biostatistics
Research, National Heart, Lung, and Blood Institute, NIH,
Bethesda, MD; 3 Vanderbilt University Medical Center,
Nashville, TN
Introduction: Rapid and profound BMD loss occur in the
ﬁrst year after allogeneic stem cell transplantation (SCT) and
attributed to steroid exposure, chronic GVHD (cGVHD),
conditioning, age and gender. However, changes in BMD in
very long-term survivors are not well understood. We eval-
uated survivors by serial DEXA scans to determine the ki-
netics as well as to identify the factors inﬂuencing long-term
BMD beyond 3 years post SCT.
Patients and Methods: 148 subjects (85 male and 63 fe-
male) underwent HLA-identical sibling SCT between 1993
and 2011. 58 survivors were informative at 10+ years and 19
at 15+ years. The median age at transplant was 36 years.
Diagnoses at transplant included CML (62), AML/MDS (56),
ALL (16), NHL/CLL (8) and others (6). 88% patients received
12-13 Gy TBI-based conditioning followed by an ex vivo T cell
depleted SCT while 12% received reduced intensity condi-
tioning and a T replete graft. The graft source was peripheral
blood in 133 (90%) andmarrow in 15(10%) patients. Hormone
replacement (in women), Calcium and vitamin D were
routinely supplemented but bisphosphonates were avoided.
Survivors were categorized by their lowest T-score as normal
BMD ( -1), osteopenia (< -1 and > -2.5) or osteoporosis (
-2.5) (WHO criteria). A T-score < -1.0 was deﬁned as bone
loss (BL). Univariate and multivariable analyses were con-
ducted to evaluate the time-trend in BMD, the trends inFigure 1.proportions of subjects with BL and the inﬂuence of age,
gender, conditioning intensity, cGVHD, prolonged cGVHD
(requiring systemic immunosuppression at 3 years), a diag-
nosis of ALL, and body mass index (BMI).
Results: At the start of analysis (3 years post SCT), signiﬁcant
BL had already occurred in 75%: 56 % had osteopenia and 19%
were osteoporotic. The forearm and spine followed by the
femur were the most common sites of osteoporosis. Follow-
up DEXA scans at 5+, 10+ and 15+ years showed signiﬁcant
changes in % with BL and in T-scores (Figure 1). The lowest T-
scores and BMD at various sites showed signiﬁcant increases
between 5 and 10 years. The femoral neck had the lowest
BMD between 5 and 15 years, signiﬁcantly lower (p<0.05)
compared to other sites apart from the forearm.
In multivariable analyses for BMD loss and osteoporosis,
bone loss was more severe with increasing age and lower
BMI but was not inﬂuenced by gender, any history of cGVHD,
prolonged cGVHD, intensity of conditioning regimen, pri-
mary diagnosis (ALL vs other) or stem cell source.
Conclusions: BMD stabilized between 3 and 5 years and
gradually improved between 5-15 years in our long-term
survivors without bisphosphonates. The femoral neck is an
anatomical site that remained vulnerable to prolongeddecline
in BMD. Age and BMI (reﬂecting general health or nutritional
status, Figure 2) weremore inﬂuential in long-term survivors
than variables indicating tissue injury, cGVHD or steroids.214
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Introduction: Metabolic syndrome could be a complication
of HSCT. Several mechanisms, including conditioning
regimen-mediated damage to the neurohormonal system
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ﬂammatory effects of the allogeneic graft and subsequent
GVHD and its therapy may play a role.
Methods: Retrospective review of medical records of 164
survivors of allogeneic HSCT between 1993 and 2010,
currently followed at the long term follow up clinic to
determine the incidence and risk factors associated with
metabolic syndrome. Metabolic syndrome was deﬁned as
clustering of risk factors for cardiovascular disease charac-
terized by abdominal obesity, atherogenic dyslipidemia,
elevated blood pressure, insulin resistance, and a proin-
ﬂammatory and prothrombotic state.
Results: Patient characteristics are summarized in Table 1.
The prevalence of metabolic syndrome was 7% in our
patient cohort. Six patients had BMI >25, 4 between 20
and 25, one <20. The prevalence rates of hyper-
triglyceridemia and microalbuminuria were 91% and 64%
respectively. Other derangements in the lipid proﬁle
included elevated total cholesterol, low HDL and high to
normal LDL in 9 patients. Thirty-six percent of the patients
had hypothyroidism and insulin resistance. Three out of the
11 survivors with metabolic syndrome had hypertension
and were being treated for it. 73% of the patients are being
followed up in preventive cardiology or endocrinology clinic.Table 1.
Patient Characteristics Number (percentages)
(n¼11)
Age at Transplant (years)
Median 6
Range 0-15
Gender
M 4 (36%)
F 7 (64%)
Ethnicity
Caucasian 5 (45%)
Hispanic 5 (45%)
Others 1 (9%)
Primary Diagnosis
Malignancy 9 (82%)
Non-Malignancy 2 (18%)
Transplant (HPCT) Characteristics
Donor
Related Donor 9 (82%)
Alternative Donor 2 (18%)
HLA Disparity
0-1 loci 11
2-3 loci 0
4-5 loci 0
Stem Cell Source
PBSC 6 (55%)
BM 4 (36%)
Cord 1 (9%)
Conditioning
Myeloablative MAC 11
Reduced Intensity RIC 0
Radiation
TBI (12 Gy, 1.5 Gy fractions) 7 (64%)
Cranial 4 (36%)
Testicular 1 (9%)
Spinal 1 (9%)
GVHD prophylaxis
Cyclosporine based 11 (100%)
Tacrolimus based 0 (0%)
+ ATG 2 (18%)
+ MTX 8 (73%)
Transplant Complications
aGVHD 2 (18%)
cGVHD 5 (45%)
GVHD treatment
Steroids 6 (54%)
ECP 4 (36%)
Others 6 (54%)Conclusions: The prevalence of metabolic syndrome in our
study cohort was more than the general pediatric population
(3.3%). Most of the patients who developed metabolic syn-
drome had been treated with radiation and had a diagnosis
of hematological malignancy. Hypertriglyceridemia and
microalbuminuria were clinical characteristics common to
most patients.
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Bronchiolitis obliterans syndrome (BOS) is a serious late
complication of allogeneic hematopoietic cell trans-
plantation (HCT) with poorly characterized risk factors and
natural history due to disease rarity. We describe the
prevalence of potential risk factors, diagnostic characteris-
tics, and natural history of 36 individuals enrolled on a
multicenter prospective trial (NCT01307462) to treat new
onset BOS after HSCT. BOS was diagnosed using modiﬁed
2005 NIH consensus criteria (FEV1<75% predicted, FEV1/
VC<0.7, and >10% FEV1 decline from pre-HCT). Possible risk
factors for lung injury included cigarette exposure in 47%
(17/36), while history of asthma or chronic obstructive lung
disease (6%) and idiopathic pneumonia syndrome (6%) were
rare. The most common treatment exposures associated
with pulmonary toxicity included cyclophosophamide
(69%), ﬂudarabine (44%), busulfan (42%) and radiation (42%).
Documented infection potentially associated with pulmo-
nary inﬂammation prior to BOS diagnosis included respi-
ratory viruses in 12/36 (33%); 4 had CMV viremia. Median
time from HCT to BOS diagnosis was 546 days (range 157-
4008). The diagnostic workup was prompted by patient-
reported symptoms in nearly half of the cohort (17/36, 47%)
and by screening pulmonary function tests (PFT) in the
remainder (53%), with median FEV1% predicted of 46.5
(range 26-67). There was a trend toward higher mean FEV1
in patients with BOS detected by PFT screening, but this was
not statistically signiﬁcant (50.2 vs 43.1, p¼0.13). While
most evaluations included chest CT (89%), few underwent
bronchoscopy (28%) or surgical biopsy (6%). Eye (68 %),
skin (56%) and mouth (56%) were the most common con-
current manifestations of chronic graft-versus-host disease
(cGVHD); 3 (9%) did not have extrapulmonary cGVHD signs
at onset of BOS. Eleven (31%) subjects required supple-
mental oxygen after BOS diagnosis and 5 (14%) currently use
oxygen. Twenty (56%) subjects were hospitalized after their
diagnosis of BOS at least once, most commonly for
